Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Invega is a prescription atypical antipsychotic containing paliperidone in an extended-release tablet. It is indicated for schizophrenia in adults and adolescents age 12 through 17 and for schizoaffective disorder in adults as monotherapy or with mood stabilizers or antidepressants.
read more about invega ...The exact therapeutic mechanism of paliperidone is not established. Its activity is thought to involve antagonism at dopamine D2 and serotonin 5-HT2A receptors. Paliperidone also has activity at alpha adrenergic and histamine H1 receptors.
Invega treats schizophrenia in adults and adolescents age 12 through 17. It also treats schizoaffective disorder in adults as monotherapy or with mood stabilizers or antidepressants. Kidney function affects dose selection and maximum daily dosing.
Adults with schizophrenia or schizoaffective disorder start at 6 mg once daily, with a recommended range of 3 mg to 12 mg daily. Adolescents with schizophrenia start at 3 mg once daily, with maximum dosing based on body weight. Extended-release tablets are swallowed whole and are not chewed, divided, or crushed.
Invega carries a boxed warning for increased mortality in older adults with dementia-related psychosis and is not approved for that use. Other serious concerns include neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, high prolactin, orthostatic hypotension, low white blood cell counts, seizures, and swallowing problems.
Invega treats schizophrenia in adults and adolescents and schizoaffective disorder in adults.
The recommended adult starting dose for schizophrenia or schizoaffective disorder is 6 mg once daily.
No. The extended-release tablets are swallowed whole and are not chewed, divided, or crushed.
Yes. The boxed warning concerns increased mortality in older adults with dementia-related psychosis.
Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/17601495/. Date Accessed October 5, 2026.
INVEGA (Paliperidone) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916. Date Accessed October 5, 2026.
Paliperidone: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a607005.html. Date Accessed October 5, 2026.
Paliperidone Extended-Release in Schizoaffective Disorder: A Randomized, Controlled Study Comparing a Flexible Dose With Placebo in Patients Treated With and Without Antidepressants and/or Mood Stabilizers. https://pubmed.ncbi.nlm.nih.gov/20814330/. Date Accessed October 5, 2026.
Tolerability and Efficacy of Paliperidone ER Compared to Olanzapine in the Treatment of Schizophrenia: A Randomized, Double-Blind, Multicentric Trial. https://pubmed.ncbi.nlm.nih.gov/22969177/. Date Accessed October 5, 2026.